Marshall Wace’s Tourmaline Bio TRML Stock Holding History

Marshall Wace’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-143,731	Closed	-$6.87M	–	3485
2025 Q3	$6.87M	Buy	+143,731	New	+$3.99M	0.01%	1066
2025 Q2	–	Sell	-99,166	Closed	-$1.51M	–	3181
2025 Q1	$1.51M	Sell	99,166 -16,925	-15%	-$271K	﹤0.01%	1595
2024 Q4	$2.35M	Sell	116,091 -22,103	-16%	-$557K	﹤0.01%	1368
2024 Q3	$3.55M	Sell	138,194 -32,253	-19%	-$538K	﹤0.01%	1133
2024 Q2	$2.19M	Buy	170,447 +31,029	+22%	+$499K	﹤0.01%	1322
2024 Q1	$3.19M	Buy	139,418 +94,422	+210%	+$3.33M	﹤0.01%	1169
2023 Q4	$1.18M	Buy	+44,996	New	+$901K	﹤0.01%	1419

Marshall Wace's TRML Position: Q4 2025 in Review

Marshall Wace sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 143,731 shares — an estimated $6.87M sold.

Marshall Wace first reported a position in TRML in Q4 2023 and held it in 7 quarters. The position peaked at $6.87M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Marshall Wace reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Marshall Wace sold 143,731 Tourmaline Bio shares in Q4 2025, an estimated $6.87M.
Marshall Wace first reported a position in Tourmaline Bio in Q4 2023 and held it in 7 quarters.
Marshall Wace's Tourmaline Bio position peaked at $6.87M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.